Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Report: Americans Are Willing to Pay More for Drugs Tested for Safety, and Also Report Differences in Side Effects and Efficacy When Switching Between Manufacturers


News provided by

MedShadow Foundation

Jul 31, 2025, 15:00 ET

Share this article

Share toX

Share this article

Share toX

Source: MedShadow / Kantar
Source: MedShadow / Kantar

MedShadow and Kantar's New Data Show Consumer Preferences and Experiences with Prescription Medications

NEW YORK, July 31, 2025 /PRNewswire-PRWeb/ -- 

  • Two-thirds of Americans say they would pay more for drugs to be regularly tested to ensure safety and efficacy. One out of three respondents would pay a premium of 50% or more.
  • When switching from a brand-name drug to a generic or from one generic to another, one out of three respondents reported differences such as less efficacy, new side effects, or more severe side effects.
  • The generic drug supply chain relies on ingredients manufactured overseas, yet most Americans believe that drugs made in the U.S. are safer or more effective.

Two-thirds of Americans say they would pay more for drugs to be regularly tested to ensure safety and efficacy. One out of three respondents would pay a premium of 50% or more.

Post this

Two-thirds of Americans say they would pay more for medications if they were regularly tested by a third party to ensure safety and effectiveness, according to a new nationwide survey of 1,000 people conducted by Kantar on behalf of MedShadow Foundation, a nonprofit focused on medication safety. Among those who are willing to pay for independent testing, one third would pay at least 50% more, one third would pay up to 25% more, and one third would pay up to 10% more.

The survey results, announced today, shed light on how Americans use and perceive brand-name and generic drugs. The vast majority (80%) of Americans who have taken a prescription in the past year take them at least once a month and report taking 3 to 4 prescriptions on average. Read a full copy of the report here.

Are prescriptions considered safe and effective?

Four out of five Americans believe that both brand-name and generic drugs are safe and effective. However, when asked about their experiences switching from a brand name to a generic or from one generic to another, a third of Americans report that they have experienced reduced effectiveness, new side effects, or more severe side effects.

"The FDA assures the public that all generics are equivalent to brand drugs—that they are just as safe and effective as brand-name drugs," said Suzanne Robotti, founder of MedShadow, former FDA Advisory Committee member, and patient advocate. "While that is the intent, that is not always the reality for patients. A small but significant amount of generic drugs are sub-quality, and that puts patients at risk."

While most Americans believe that generics are exactly the same and are held to the same standards as brand-name drugs, the majority of Americans also feel that U.S.-made drugs are safer or more effective than drugs made overseas. More than 90% of the drugs taken in the U.S. are generics, and up to 86% of the active ingredients in those drugs are manufactured overseas.

Throughout the survey, age had a statistically significant bearing on responses. For example, 74% of respondents aged 44 and below believe that prescriptions made in the U.S. are more effective, compared to 32% of those 45 and over. See more age-relevant stats here.

What happens when people switch between generics?

Two-thirds of Americans have switched from a brand-name to a generic prescription or from one generic to another, according to the survey. A third of Americans also cite noticeable differences with generics, often for more than one refill. Sometimes the new generic was less effective (than the brand name 23% / than prior generic 31%), other times it caused new side effects (vs. the brand name: 19% / vs. prior generic: 23%), and sometimes the new generic caused more severe side effects (21% for both).

In most cases, the differences in efficacy and new side effects were experienced only one time, but for those who experienced more severe side effects, half of respondents said it happened 2-3 times.

"Experts and reporters, including at MedShadow, have been sounding the alarm," Robotti continued. "Our research and the overwhelming response to our social media posts demonstrate that many people have experienced generic drug failure. With this research in hand, we call on doctors to believe patients when they say a drug is not working and help them find one that does. And, we call on the FDA to put better safety checks in place for the drugs made both here and in other countries to keep Americans healthy."

Survey methodology

This research was conducted online among 1,000 people across the United States. Respondents were sourced from the Kantar Profiles Respondent Hub. All interviews were conducted as online self-completion between June 20 and 25, 2025 and collected to be census representative for age and gender. All respondents reported that they have taken at least one prescription drug in the past 12 months.

MedShadow regularly covers issues surrounding prescription drugs, including a series of articles and webinars called Investigating Generic Drugs. Learn more at MedShadow.org, sign up for the newsletter for the latest updates, and read the full survey results.

About MedShadow Foundation

MedShadow Foundation is a nonprofit that focuses on the safest ways to take over-the-counter and prescription medications. Medications have many benefits, but knowing how to balance these against their potential side effects is essential. Side effects can sometimes be difficult to recognize, so MedShadow works to illuminate and explain medication reactions that may be otherwise minimized or obscured. medshadow.org

About Kantar

Kantar is the world's leading marketing data and analytics business and an indispensable brand partner to the world's top companies. It combines the most meaningful attitudinal and behavioral data with deep expertise and advanced analytics to uncover how people think and act. It helps clients understand what has happened and why and how to shape the marketing strategies that shape their future. Kantar's Profiles division is the industry's most trusted strategic partner for essential data collection. With access to 170 million+ people in over 100 global markets, they provide unrivalled global reach with local relevancy through a range of data solutions. Due to their unparalleled innovations and investment into AI-driven anti-fraud, panel management technology and research design, the Profiles Team at Kantar delivers quality with flexibility. kantar.com/solutions/research-services

Media Contact

Lisa Jaycox, MedShadow Foundation, 1 646-244-6992, [email protected], https://medshadow.org/

SOURCE MedShadow Foundation

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.